DiaMedica Therapeutics (DMAC) said Wednesday that it has received regulatory approval from the South African Health Products Regulatory Authority to begin a mid-stage clinical trial with DM199 to treat preeclampsia.

The company said it will conduct the planned two-part mid-stage trial at Tygerberg Hospital in Cape Town, South Africa.

DiaMedica said it expects dosing to begin in Q4, with topline results from part 1a of the trial expected in H1 next year.

Shares of the company were up 1.7% in recent Wednesday premarket activity.

Price: 4.7300, Change: +0.08, Percent Change: +1.72